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Abstract
Objectives Contrast-enhanced spectral mammography
(CESM) is a promising problem-solving tool in women
referred from a breast cancer screening program. We
aimed to study the validity of preliminary results of
CESM using a larger panel of radiologists with different
levels of CESM experience.
Methods All women referred from the Dutch breast cancer
screening program were eligible for CESM. 199 consec-
utive cases were viewed by ten radiologists. Four had
extensive CESM experience, three had no CESM expe-
rience but were experienced breast radiologists, and
three were residents. All readers provided a BI-RADS
score for the low-energy CESM images first, after which the
score could be adjusted when viewing the entire CESM exam.
BI-RADS 1-3 were considered benign and BI-RADS 4-5
malignant. With this cutoff, we calculated sensitivity, specific-
ity and area under the ROC curve.
Results CESM increased diagnostic accuracy in all readers.
The performance for all readers using CESM was: sensitivity
96.9 % (+3.9 %), specificity 69.7 % (+33.8 %) and area under
the ROC curve 0.833 (+0.188).
Conclusion CESM is superior to conventional mammogra-
phy, with excellent problem-solving capabilities in women
referred from the breast cancer screening program. Previous
results were confirmed even in a larger panel of readers with
varying CESM experience.
Key Points
•CESM is consistently superior to conventional mammography
• CESM increases diagnostic accuracy regardless of a
reader’s experience
• CESM is an excellent problem-solving tool in recalls from
screening programs
Keywords Breast cancer . Contrast-enhanced spectral
mammography . CESM . Contrast-enhanced dual energy
mammography . CEDM
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Introduction
In breast imaging, mammography plays a pivotal role in breast
cancer detection and evaluation. Although the diagnostic ac-
curacy of conventional mammography has improved signifi-
cantly during the last decade due to the introduction of full-
field digital mammography (FFDM), its accuracy remains de-
pendent on the density of the fibroglandular tissue [1].
Several new mammographic techniques have been intro-
duced to improve FFDM’s diagnostic accuracy, the most re-
cent one being contrast-enhanced spectral mammography
(CESM). Previous studies have shown that CESM is superior
to FFDM for breast cancer detection, even equalling the per-
formance of breast MRI [2–4]. It was also demonstrated that
CESM was clinically feasible even in a study population with
a low disease prevalence, i.e., recalls from a breast cancer
screening program [5]. Although all diagnostic performance
parameters in this study improved when using CESM, the
most important changes were observed regarding specificity
(increasing from 42% to 87.7%) and positive predictive value
(PPV, increasing from 39.7 % to 76.2 %). These results
showed that in this population CESM has great potential as
a problem-solving tool. However, they were based on an in-
terim analysis of the institution’s first 113 patients, and read-
ings were performed by only two radiologists who were ex-
perienced in reading CESM exams.
Reproducibility of initial findings is an important step in
the evaluation of every new diagnostic technique. Therefore,
we aimed to compare the diagnostic performance of FFDM
and CESM using a larger panel of radiologists with different
levels of CESM experience [5].
Materials and methods
Patient selection
For this retrospective study, the requirement for obtaining in-
formed consent was waived by the local ethics committee. All
women recalled from the breast cancer screening program
who were referred to our institution for assessment in the
period from November 2012 until October 2013 were eligible
to undergo CESM.Womenwith a known allergy for iodinated
contrast agents and those who had an increased risk for
developing contrast induced nephropathy were excluded.
The latter was established using the ESUR guidelines on
Contrast Media, as stated by the European Society of
Urogenital Radiology (ESUR) [6].
Imaging protocol and analysis
The principle of the CESM technique was described else-
where [7]. In short, a low-energy (LE) and a high-energy
image (HE) are obtained of both breasts in the standard
mediolateral oblique (MLO) and craniocaudal (CC) views.
The LE image provides maximal soft tissue contrast and is
similar to a conventional mammogram [8–10]. The HE image
is not of diagnostic quality and is used for post-processing
purposes only. Both images are used to create a recombined
image which shows enhancement of lesions [7].
All CESM exams were performed on a single CESM unit
(Senographe* Essential with Senobright* upgrade, GE
Healthcare, Chalfont St Giles, United Kingdom) using a
non-ionic, monomeric, low-osmolar contrast agent at a dose
of 1.5 mL/kg body weight (iopromide, Ultravist® 300, Bayer
Healthcare, Berlin, Germany). Iodinated contrast was intrave-
nously administered with a flow rate of 3 mL/s two minutes
prior to image acquisition. Both breasts were imaged in MLO
and CC views with additional views to be requested by the
radiologist if deemed necessary at the time of the exam.
Patients were monitored for a minimal period of 30 minutes
afterwards to rule out late adverse contrast reactions.
The panel of readers consisted of seven dedicated breast
radiologists and three residents. Of the dedicated breast radi-
ologists, four had 2 years of experience with CESM (the ex-
perienced CESM users). Their range of experience with con-
ventional mammography was 2 to 6 years. The remaining
three dedicated breast radiologists had between 3 and 25 years
of experience with mammography but no previous experience
whatsoever regarding CESM. The residents had limited
CESM and mammography experience (8 weeks full time as
part of their residency) and were trained in that period by the
experienced CESM radiologists.
The panel of readers was allowed to learn the reason
of referral from the screening program (similar to every-
day clinical practice), and started by evaluating the LE
image first. An initial breast imaging reporting and data
system (BI-RADS) score of 1 to 5 had to be provided
before evaluating the entire CESM exam, including both
the LE and recombined images, during the same reading
session. The reader was then allowed to upgrade or
downgrade their BI-RADS score if deemed necessary.
All radiologists were blinded for each other’s scores,
previous or follow-up examinations and final diagnosis.
Readers were divided into three subgroups: experienced
CESM readers, non-experienced CESM readers and res-
ident readers.
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Standard reference procedures used to assess true disease
status
To assess the true disease status of a recalled patient, one of the
strategies below was followed [11].
In the case of suspicious calcifications or masses, a biopsy
was performed under ultrasound guidance or stereotactic
guidance with histology serving as gold standard. In all cases
of cysts, a targeted ultrasound examination was performed in
combination with aspiration of the cyst to prove its non-solid
nature. In cases where superposition of normal fibroglandular
tissue was suspected, at least one additional view of the breast
containing the suspicious lesion followed by targeted ultra-
sound was performed. If no abnormality was found on addi-
tional imaging, women were discharged according to the NHS
Breast Screening Program (NHSBSP) Clinical Guidelines for
Breast Cancer Screening Assessment and our national guide-
lines [12, 13].
Statistical analysis
BI-RADS scores 1–3 were considered benign and BI-RADS
4–5 malignant. Using these cutoff values, sensitivity, specific-
ity, positive predictive value (PPV) and negative predictive
value (NPV) of the readers were calculated. Interpretation of
images from the same set of patients by multiple readers are
likely to be correlated. Moreover, because FFDM and CESM
were performed in the same study population, the results of
both tests are also correlated. Ignoring correlation can lead to
misleadingly small estimates of the standard error and conse-
quently to 95 % confidence intervals which are too small. To
adjust for the correlated data structure, variance of the sensi-
tivity and specificity for all readers and for subgroups of
readers (experienced in CESM reading, non-experienced in
CESM reading and residents) were adjusted with the variance
inflation factor (VIF). The variance of the difference in sensi-
tivity and specificity between FFDM and CESM was estimat-
ed based on these adjusted variances and the covariance be-
tween FFDM and CESM results. Adjusted 95 % confidence
intervals (CI) were derived using an excel spreadsheet provid-
ed by Genders et al. [14]. Receiver operating characteristic
(ROC) curves were constructed for both imaging modalities
and areas under the curve (AUC), with corresponding 95%CI
calculated using bootstrap analyses (2000 repetitions). The
DeLong test was used for paired comparison of the AUC of
FFDM and CESM [15]. Fleiss’ generalized kappa coefficient
was used to determine the inter-rater reliability for the image
analysis of both FFDM and CESM.
In a separate analysis, false negative and false positive
findings were further evaluated. All false negatives were ana-
lyzed to identify potential CESM pitfalls. For false positives
findings, cases were included for this subanalysis if five or
more readers (i.e., more than half of the reading panel) scored
this case as being false positive on CESM. All statistical anal-
yses were performed using SPSS (IBM Corp. Released 2011.
IBM SPSS Statistics for Windows, Version 20.0. Armonk,
NY: IBM Corp.) and the pROC package in R (Version: 1.7.2
released on 6 April 2014) [15]. P values≤0.05 were consid-
ered statistically significant.
Results
A total of 199 consecutive patients who were referred to our
institution from the breast cancer screening program
underwent CESM as part of their workup (mean age
58.4 years, range 49–75 years). Most recalls were caused by
masses (76.4 %), followed by calcifications (15.1 %), asym-
metry (5.0 %) and architectural distortions (3.5 %). At final
diagnosis, 29.6 % of the cases proved to be malignant.
Detailed patient characteristics were summarized in Table 1.
Table 2 presents detailed information of sensitivity and
specificity for all readers. For the entire reading panel, diag-
nostic performance parameters improved when using CESM.
Mean sensitivity increased from 93.0 % to 96.9 % and mean
specificity from 35.9 % to 69.7 %. Mean PPV and NPV in-
creased from 38.7 % and 92.6 % to 58.2 % and 98.2 %, re-
spectively. The ROC curves showed an improvement in diag-
nostic performance for all readers when using CESM (Fig. 1).
For all readers combined, the AUC value increased from
0.645 to 0.833 (p<0.0001). Detailed results for the compari-
son of CESM and FFDM are presented in Table 3. Sensitivity
increased for all reader panels, but was only significantly in-
creased for resident readers (p=0.011) and for all readers to-
gether (p=0.0002). Looking at the difference in sensitivity
and specificity for CESM and FFDM, both increased for all
readers using CESM. For all subgroups of reader panels, spec-
ificity was significantly increased. The inter-rater variability
was considered to be excellent with a kappa-value of 0.89.
Ten cases (5 %) with false negative CESM findings were
observed. An overview of the final diagnosis, tumour charac-
teristics and the number of readers that scored the individual
case as false negative is presented in Table 4. Three readers
had no false negative scores with CESM.All other readers had
at least one false-negative finding on CESM (median two
cases, range 1–4).
The mean number of false positive cases was 42 (21.1 %,
range 19-58), with an average for the experienced CESM
readers of 31 cases (15.6 %). The experienced FFDM readers
showed an average of 37 false positive cases (18.6 %), where-
as the residents showed 54 false positive findings (27.1 %). A
total of 40 cases (20.1 %) were scored as false positive by five
or more readers using CESM. In this subgroup, the most com-
mon causes were fibroadenomas (n=10), followed by super-
position densities (n=8), and cysts (n=3). A detailed summa-
ry of this subanalysis is presented in Fig. 2.
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Discussion
CESM is a promising new breast imagingmodality. In CESM,
an iodine-based contrast agent is intravenously administered,
after which dual-energy mammography is performed. As a
result, the radiologist can view a low-energy image (which
is similar to a conventional FFDM) and a recombined image,
showing areas of enhancement [7, 16]. In a previous study, it
was shown that CESM is an excellent problem-solving tool
for women recalled from the breast cancer screening program
[5]. However, these results were based on an interim analysis
of the institution’s first 113 cases read by only two radiologists
experienced in CESM. Our current study shows that these
results were reproducible, even in a large number of cases read
by a panel of ten different radiologists with varying experience
in reading CESM exams. Mean sensitivity increased from
93.0 % to 96.9 % and mean specificity from 35.9 % to
69.7 %. Mean PPV and NPV increased from 38.7 % and
92.6 % to 58.2 % and 98.2 %, respectively.
Several publications have studied the diagnostic perfor-
mance of CESM (Table 5) [2–5, 8, 17–22]. In these studies,
the mean sensitivity of CESM varied from 77.8 to 100.0 %,
whereas mean specificity (if available) varied from 41 to
87.7 %. In some studies, specificity could not be calculated
since all included subjects were diagnosed with breast cancer
[3, 8, 19]. One study did not provide specificity, but accuracy
instead [22].The disease prevalences in the other studies (ex-
cept the study by Lobbes et al.) were higher than our popula-
tion (range 36-100 %). The reported prevalence of 36 % con-
cerned a study population where all included subjects had
microcalcifications without an associated mass [21].
However, breast cancer prevalence in clinical practice is low.
It is interesting to study the diagnostic performance of CESM
in populations with low breast cancer prevalence since it
should not result in a large number of false-positive findings.
For this reason, Lobbes et al. studied CESM’s diagnostic
performance in women recalled from breast cancer screening,
who had a breast cancer prevalence of 28.3 % [5]. They found
that (when compared to FFDM) sensitivity increased from
96.9 % to 100.0 % and NPV increased from 97.1 % to
100.0 %. Interestingly, the largest improvements were ob-
served for specificity and PPV, increasing from 42.0 % and
39.7 % to 87.7 % and 76.2 %, respectively. It was concluded
that CESMwas an excellent problem-solving imaging modal-
ity for recalls from the breast cancer screening program, able
to detect breast cancer accurately, while establishing false-
positive recalls confidently.
An important limitation of the study by Lobbes et al. was
that two readers experienced with CESM read the cases.
However, in order to become clinically implemented, the re-
producibility of test results of every new diagnostic imaging
modality should be validated, preferably in larger study pop-
ulations using multiple readers. Therefore, we used a panel of
ten different readers with different experience in FFDM and
CESM to evaluate 199 consecutive CESM exams of women
recalled from the breast cancer screening program. Our cur-
rent results confirmed prior observations, with an increase of
all diagnostic performance parameters when using CESM,
especially with respect to specificity and PPV. These improve-
ments were observed for all readers, independent of their level
of CESM experience. Current results are in line with another
previously published study with relatively lower disease
Table 1 Patient characteristics: age, final diagnosis for malignant and





Final Diagnosis Percentage (n = 199)
Malignant
Invasive ductal carcinoma 22.1
Invasive lobular carcinoma 4.0
Ductal carcinoma in situ 2.5
Invasive mucinous carcinoma 0.5




Reactive changes / benign 1.5
Apocrine changes / metaplasia 3.5
Papilloma 1.5
Superposition 28.1









Lobular carcinoma in situ 0.5
Flat epithelial atypia 0.5
Total 100.0







ER: estrogen receptor, PR: progesterone receptor, HER2/neu: Human
Epidermal growth factor Receptor 2
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prevalence. Luczyńska et al. studied 157 breast lesions (breast
cancer prevalence 38.3 %) using both FFDM and CESM [4].
Sensitivity of CESMwas 100%, with a PPVand NPVof 77%
and 100 %, respectively, with an AUC of 0.86. However, in
their study only a single reader was used to view the exams.
CESM has potential pitfalls, resulting in both false negative
or false positive findings. In a study by Thibault et al., six false
negative findings were observed: two invasive ductal carcino-
mas outside the field of view and four invasive lobular cancers
[23]. Fallenberg et al. (using three readers) found that when
CESMwas solely used, one cancer was missed by all readers,
four cancers were missed by two, and three by one reader [8].
In our study, a total of ten false negative cases were observed,
scored incorrectly by one or more readers. The cancers that
were overlooked bymore than one reader were analyzed case-
by-case. These were: one invasive grade 2 ductal carcinoma
missed by five readers, one invasive grade 2 ductal carcinoma
missed by three readers, and one grade 1 invasive mucinous
carcinoma missed by two readers. These cases are illustrated
in Fig. 3. Two cases consisted of a focal asymmetry with ill-
defined margins, only partly visible on the MLO view only.
These lesions showed only subtle or no enhancement on the
recombined images (Fig. 3a and b). Among the readers that
missed these lesions were experienced CESM users as well as
non-experienced CESM users and residents. Future develop-
ments such as computer aided detection systems for CESM or
contrast-enhanced digital breast tomosynthesis could poten-
tially reduce the risk of missing these types of lesions. The
third case (missed by two readers) consisted of an ill-defined
mass visible on both CC andMLO views with a central coarse
calcification without any enhancement on the recombined im-
ages. Despite the lack of enhancement, it does not represent a
typical ‘eclipse’ sign, which is the CESMappearance of a cyst,
consisting of a dark ‘void’ on the recombined images com-
bined with a subtle rim enhancement, resembling a solar
eclipse [5]. This atypical appearance of the eclipse sign togeth-
er with its irregular margin warranted additional targeted ul-
trasound. Final pathology showed a grade 1 mucinous carci-
noma (Fig. 3c). Mucinous carcinomas can be a CESM pitfall
due to lack of enhancement. This case demonstrates that
Table 2 Diagnostic performance
of FFDM and CESM for all ten
readers. Diagnostic performance
parameters were presented as
percentages with 95% confidence
intervals in parentheses
Reader Exam Sensitivity Specificity
Experienced CESM Reader 1 FFDM 86.4 % (75.0–93.9 %) 67.1 % (58.7–74.8 %)
CESM 93.2 % (83.5–98.1 %) 86.4 % (79.6–91.6 %)
Experienced CESM Reader 2 FFDM 96.6 % (88.2–99.4 %) 26.4 % (19.3–34.5 %)
CESM 98.3 % (90.8–99.7 %) 70.7 % (62.4–78.1 %)
Experienced CESM Reader 3 FFDM 94.9 % (85.8–98.9 %) 49.3 % (40.7–57.8 %)
CESM 100.0 % (93.8–100.0 %) 75.7 % (67.7–82.6 %)
Experienced CESM Reader 4 FFDM 98.3 % (90.8–99.7 %) 15.0 % (9.5–22.0 %)
CESM 100.0 % (93.8 %–100.0 %) 75.7 % (67.7–82.5 %)
Mean FFDM 94.1 % (89.6–98.5 %) 39.5 % (19.7–59.2 %)
Mean CESM 97.6 % (95.1–100 %) 77.1 % (71.5–82.7 %)
Non-Experienced CESM Reader 1 FFDM 98.3 % (90.8–99.7 %) 37.8 % (29.8–56.4 %)
CESM 100.0 % (93.8–100.0 %) 67.1 % (58.7–74.8 %)
Non-Experienced CESM Reader 2 FFDM 96.6 % (88.2–99.5 %) 21.4 % (14.9–29.1 %)
CESM 94.9 % (85.8–98.8 %) 64.3 % (55.7–72.2 %)
Non-Experienced CESM Reader 3 FFDM 89.9 % (79.1–96.1 %) 40.7 % (32.5–49.3 %)
CESM 93.2 % (83.5–98.1 %) 72.8 % (64.7–80.0 %)
Mean FFDM 94.9 % (90.8–99.0 %) 33.3 % (23.7–42.9 %)
Mean CESM 95.9 % (92.9–98.9 %) 68.0 % (64.1–72.1 %)
Resident
Reader 1
FFDM 89.8 % (79.1–96.1 %) 32.8 % (25.1–41.3 %)
CESM 96.6 % (88.2–99.4 %) 58.5 % (49.9–66.8 %
Resident
Reader 2
FFDM 93.2 % (83.5–98.0 %) 36.4 % (36.4–44.9 %)
CESM 96.6 % (88.2–99.4 %) 64.2 % (55.7–72.2 %)
Resident
Reader 3
FFDM 86.4 % (75.0–93.9 %) 32.1 % (24.5–40.5 %)
CESM 96.6 % (88.2–99.5 %) 61.4 % (52.8–69.5 %)
Mean FFDM 89.8 % (79.2–96 %) 33.7 % (28.6–42.2 %)
Mean CESM 96.6 % (95.4–98.2 %) 61.3 % (52.8–69.5 %)
All Readers Mean FFDM 93.0 % (90.3–95.8 %) 35.9 % (27.3–44.5 %)
CESM 96.9 % (93.2–100.0 %) 69.7 % (64.8–74.6 %)
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readers should not only focus on the recombined images.
They are an adjunct to the mammographic images, not a
replacement.
CESM also generates false positive findings. In the study by
Badr et al. enhancement was observed in 33 % of 27 benign
lesions [24]. Jochelson et al. detected two false positive results
in 52 patients (4%) using CESM [3]. Lobbes et al. detected five
false positive findings in a population of 113 women [5].
Luczyńska et al. found 35 (20 %) false positive lesions with
CESM compared to 50 (29 %) with conventional
mammography [4]. Similar to our observations, most of these
lesions were caused by fibroadenomas (n=26) or some other
benign solid breast lesion. Although these findings resulted in
tissue sampling that could have been avoided, its prevalence is
low and does not outweigh the improved cancer detection rates
caused by CESM when compared to FFDM.
This study showed that CESM remains an excellent problem-
solving tool for patients recalled from breast cancer screening,
even when radiologists less experienced in CESM are reviewing
the images. This implies that readingCESMexams has hardly any
FFDM: 0.618 ( 0.587 - 0.649)
CESM: 0.790 ( 0.763 - 0.818)
p < 0.0001
Resident reviewers
FFDM: 0.668 (0.614 - 0.668)
CESM: 0.821 ( 0.793 - 0.847)
p < 0.0001
Non – Experienced reviewers
FFDM: 0.645 (0.629 – 0.661)
CESM: 0.833 (0.819 - 0.847)
p < 0.0001
ALL reviewers
FFDM: 0.668 ( 0.642 - 0.694)
CESM: 0.875 ( 0.856 – 0.894)
p < 0.0001
Experienced reviewers
FFDM CESM Reference line
a b
dc
Fig. 1 Average ROC curves for
all readers (a), experienced
CESM readers (b), experienced
FFDM readers (c) and resident
readers (d). AUC values for
FFDM and CESM given with
confidence intervals in
parenthesis. Differences in AUC
between FFDM and CESM were
significantly increased for all
subgroup of reader panels, p-
values given per subgroup of
reader panel
Table 3 Difference (Δ) in sensitivity and specificity of CESM and FFDM with 95 % confidence intervals (CI) in parenthesis. p values < 0.05 are
considered significant
Δ Sensitivity CESM-FFDM (95 % CI) p value (<0.05 significant) Δ Specificity CESM-
FFDM (95 % CI)
p value (<0.05
significant)
Experienced CESM readers 0.035 (-0.009–0.079) p= 0.114 0.376 (0.193–0.559) p= 0.000056
Non-experienced CESM readers 0.010 (0.036–0.056) p= 0.667 0.348 (0.254–0.442) p< 0.00001
Resident Readers 0.068 (0.016–0.120) p= 0.011 0.276 (0.223–0.329) p< 0.00001
All readers 0.038 (0.018–0.058) p= 0.0002 0.338 (0.267–0.409) p< 0.00001
CESM false negative findings
4376 Eur Radiol (2016) 26:4371–4379
learning curve. Introduction into everyday clinical practice is safe
and feasible [5]. Using CESM in recalled patients increases spec-
ificity and PPV, thus providing the radiologist with a confident
final diagnosis in cases of false positive recalls. For example, if
recalled patients have a negative CESM exam, the highNPVrules
out the presence of breast cancer, preventing people from under-
going additional exams (such as breast MRI) or follow-up exams.
Nevertheless, prospective randomized controlled trials are neces-
sary to compare the standard work-up using conventional breast
imaging with CESM-based work-up, in order to accept CESM as
a primary imaging tool in the work-up of recalled patients.
Study limitations
Our study had some limitations. Earlier results were previous-
ly published and consisted of 113 cases read by two experi-
enced CESM viewers [5]. In the current study, these two
readers were again participating in the scoring of the exams,
thus re-scoring these exams. However, the data used was
anonymized and the time period between the two scoring
rounds was more than one year, minimizing the chances of
introducing recall bias in these 113 cases. The remaining 86
cases were also new to these two readers. To prove that no
recall bias was introduced, we performed additional analyses.
In the previous publication, the AUC of ROC curve was 0.779
for mammography, increasing to 0.976 using CESM [5].
These were the results of 113 cases. After more than one year,
two readers reviewed these 113 cases again as part of the
current study, achieving a diagnostic performance as
expressed by the AUC value of 0.831 for mammography
and 0.971 using CESM. The AUC value of the final 86
(completely new) cases was 0.881 for mammography and
0.977 for CESM. This shows that no recall bias was intro-
duced during the re-reading of the first 113 cases by these
Table 4 Diagnosis of false negative cases and the number of readers
that scored them as false negative. Experience level is indicated of the
number of readers that missed the lesion on CESM. In addition, lesion
characteristics such as diameter (given in millimetres), histologic grade,
DCIS grade and hormonal receptor status (ER, PR, HER2NEU) are
given. Hormone receptor status in case of pure DCIS is not evaluated
and therefore not available (n/a) for these cases
Final diagnosis Number of readers scoring false negative Tumour Characteristics
Histology Experienced CESM Non- experienced CESM Resident Total Diameter in mm Grade ER PR HER2/neu
Invasive ductal carcinoma 1 2 2 5 14 2 + + -
Invasive ductal carcinoma 1 1 1 3 22 2 + + +
Invasive mucinous carcinoma - 2 - 2 18 1 + + -
Invasive ductal carcinoma - 1 - 1 20 2 + - -
Invasive ductal carcinoma 1 - - 1 7 1 + + -
Invasive ductal carcinoma 1 - - 1 4 1 + - -
Invasive ductal carcinoma - - 1 1 16 2 + + -
Ductal carcinoma in situ - 1 - 1 10 2-3 n/a n/a n/a
Invasive lobular carcinoma - - 1 1 5 2 + + -
Ductal carcinoma in situ - - 1 1 26 3 n/a n/a n/a













Lobular carcinoma in situ
Flat epithelial atypia










Fig. 2 Overview of number of
cases and diagnosis of false-
positive findings. These cases
were scored as false-positive
cases by five or more readers
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two readers. For the remaining eight readers, all 199 cases were
completely new. For reasons of comparison, we decided to
include the complete data of the two experienced CESM re-
viewers to provide an overview of the performance of each
reader for the entire case collection. However, in order to further
assess the reproducibility of these results, it would be valuable
to conduct a study consisting of an entirely different population,
preferably in different institutes using units of different vendors,
which are now becoming commercially available. Second,
there was no follow-up of cases with superposition of
fibroglandular tissue as final diagnosis. However, our current
imaging strategy of these cases complies with the NHSBSP’s
Clinical Guidelines for Breast Cancer Screening Assessment
[12]. This strategy is safe, with the chances of overlooking
breast cancer being minimal, as was additionally proven by
an institutional quality control covering almost 600 recalls from
screening (personal communication). Third, all cases were re-
calls from the national breast cancer screening program. This
introduced some selection bias since all patients were pre-
selected by two screening radiologists. In addition, readers were
not blinded for the reason of referral. However, the latter two
limitations reflect everyday clinical practice of the work-up of
recalled women. Finally, the additional value of (targeted) ul-
trasound next to FFDM was not taken into account since we
wished to focus on the additional value of adding contrast and
the recombined images to conventionalmammography. Indeed,
additional ultrasound could also clarify some findings that
proved to be benign (such as a cyst). Since Dromain et al.
showed that CESM is also superior to mammography and ul-
trasound combined [2], it would still be recommendable to use
CESM as a primary imaging tool for recalled patients.
Conclusion
The diagnostic performance of CESM is superior to FFDM in
women recalled from the breast cancer screening program,
confirming previously published results. Even when used by
less experienced CESM readers, CESM increases all diagnos-
tic accuracy parameters, especially specificity and positive
predictive value.
Table 5 Studies comparing
CESM and Mammography:
number of patients included,
sensitivity and specificity given
for CESM
Study Number of patients (n) Sensitivity (%) Specificity (%) Disease prevalence (%)
Lewin et al. [17] 26 100 86.7 50
Dromain et al. [2] 144 93 63 56.3
Dromain et al. [18] 110 91.9 46 56.7
Fallenberg et al. [19] 80 100 - 100
Jochelson et al. [3] 52 96 - 100
Fallenberg et al. [8]a 118 94.7*/95** - 100
Lobbes et al. [5] 113 100 87.7 28
Luczyńska et al. [4] 152 100 41 76
Cheung et al. [20] 89 92.7 67.9 72
Luczyńska et al. [22] 118 100 Not provided 68.6
Cheung et al. [21]b 52 90.9 83.78 37.7
Disease prevalence based on number of lesions analysed in the included population is given, calculated from data
given in study




Fig. 3 Example of false negatives cases. Low-energy images at the top
with corresponding re-combined images underneath. A: infiltrating grade
2 ductal carcinoma with grade 3 ductal carcinoma in situ (curved arrow),
B: invasive grade 2 ductal carcinoma (arrow head) and C: grade 1
mucinous carcinoma (straight arrow)
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